BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38266162)

  • 41. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; CaliĆ² A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Xp11.2 translocation renal cell carcinoma with SFPQ/PSF-TFE3 fusion gene: A case report with unusual histopathologic findings.
    Ishikawa N; Nagase M; Takami S; Nagano N; Araki A; Iwahashi T; Yamauchi N; Yamasaki T; Shiina H; Maruyama R
    Pathol Res Pract; 2019 Sep; 215(9):152479. PubMed ID: 31153695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
    Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
    Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case of PSF-TFE3 gene fusion in Xp11.2 renal cell carcinoma with melanotic features.
    Zhan HQ; Chen H; Wang CF; Zhu XZ
    Hum Pathol; 2015 Mar; 46(3):476-81. PubMed ID: 25582502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
    Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
    Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
    Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
    Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
    Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
    Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis.
    Lee HJ; Shin DH; Kim SY; Hwang CS; Lee JH; Park WY; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
    Histopathology; 2018 Nov; 73(5):758-766. PubMed ID: 29968390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
    Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
    Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.
    Tsuda M; Davis IJ; Argani P; Shukla N; McGill GG; Nagai M; Saito T; LaƩ M; Fisher DE; Ladanyi M
    Cancer Res; 2007 Feb; 67(3):919-29. PubMed ID: 17283122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with lymph node metastasis diagnosed after an injury accident: report of a case].
    Chen Y; Kang S; Qiu J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):123-4. PubMed ID: 24742576
    [No Abstract]   [Full Text] [Related]  

  • 56. Structural basis for the dimerization mechanism of human transcription factor E3.
    Yang G; Li P; Liu Z; Wu S; Zhuang C; Qiao H; Zheng L; Fang P; Lei C; Wang J
    Biochem Biophys Res Commun; 2021 Sep; 569():41-46. PubMed ID: 34225079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
    He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
    Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
    Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
    Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
    Ye H; Qin S; Li N; Lin M; Xu Y; Li X
    Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.